CellaVision AB: Interim Report January-September 2015
(Thomson Reuters ONE) -
Veterinary order resulted in record quarter for CellaVision
July 1-September 30, 2015 January 1-September 30, 2015
* Net sales increased by 58 % to SEK * Net sales increased by 23 % to SEK
74.5 million (47.0); adjusted for 177.8 million (144.4); adjusted
exchange rate effects growth was for exchange rate effects growth
47 % was 13 %
* Operating profit increased to SEK * Operating profit increased to SEK
30.3 million (7.7) 49.0 million (26.0)
* The operating margin was 40.6 * The operating margin was 27.6
(16.3) % (18.0) %
* Profit before tax increased to SEK * Profit before tax increased to SEK
30.3 million (7.9) 48.7 million (26.8)
* Earnings per share were SEK 1.02 * Earnings per share were SEK 1.58
(0.20) (0.83)
CEO's comments
The third quarter of 2015 was a fantastic quarter for CellaVision, with
historically strong growth in both sales and profitability. Sales increased by
58 percent compared with the same period in the previous year and the operating
margin was 41 percent, to be compared with an operating margin of 16 percent in
the corresponding quarter in 2014. The main explanation for this very sound
growth is the order for veterinary medicine laboratories in North America.
Deliveries and installation have gone according to plan and final delivery will
be completed before the end of the current year. For the full year 2015 we
continue to expect an operative operating profit in excess of SEK 65 million.
The veterinary order had a major impact on growth in the Americas, which was
113 percent in the quarter. APAC also reported a positive trend, with sales
growth of 50 percent and satisfactory growth in Japan and China that are our
priority markets in the region.
The human market continues to be the most important for CellaVision and
constitutes about 15,000 large laboratories, where we have currently penetrated
about 12 percent. The corresponding market for large veterinary laboratories is
currently estimated to be about 500. We are now at a stage where we are
identifying the most important success factors in the veterinary market, a
market where we see long term growth potential.
CellaVision's growth ambitions also include expanding the product offer to the
approximately 100,000 small and medium-sized laboratories in the human segment
and the approximately 5,000 small laboratories in the veterinary segment.
Development of the future technology platform adapted to this type of laboratory
passed an important milestone during the quarter, when the prototype phase was
concluded and the project moved into a concrete development phase. CellaVision
implemented a new organization during the quarter, which includes greater focus
on sales and marketing. As part of this, Mattias Lundin has taken up the newly
established position of VP Global Sales. During the quarter we also established
a new regional office in Shanghai with responsibility for our APAC operations.
We took several important steps in the quarter towards achieving our vision to
be a leader in global digitization and automation of blood analyses for both the
human and veterinary segments. Our method contributes to improved patient
diagnostics, streamlining and reduced healthcare costs.
Zlatko Rihter, President and Chief Executive Officer
Key Ratios
(MSEK) Jul-Sep Jul-Sep Jan-Sep Jan-Sep Jan-Dec
2015 2014 2015 2014 2014
-------------------------------------------------------------------------------
Net sales 74.5 47.0 177.8 144.4 216.9
-------------------------------------------------------------------------------
Gross profit 54.8 30.4 127.8 94.6 145.1
-------------------------------------------------------------------------------
Operating profit 30.3 7.7 49.0 26.0 42.8
-------------------------------------------------------------------------------
Operating margin, 40.6 16.3 27.6 18.0 19.7
%
-------------------------------------------------------------------------------
Profit/loss before 30.3 7.9 48.7 26.8 43.4
tax
-------------------------------------------------------------------------------
Cash flow for the 32.4 12.3 46.7 0.6 -6.0
period
-------------------------------------------------------------------------------
Questions concerning the report can be addressed to:
Zlatko Rihter, CEO, CellaVision AB, Tel: 0733-62 11 06. E-post:
zlatko.rihter(at)cellavision.se
Magnus Blixt, CFO, CellaVision AB, Tel: 0708-33 81 68. E-post:
magnus.blixt(at)cellavision.se
Link text: CellaVision AB Interim Report January-September 2015
CellaVision AB Interim Report January-September 2015:
http://hugin.info/132164/R/1965223/717470.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via GlobeNewswire
[HUG#1965223]
Unternehmensinformation / Kurzprofil:
Datum: 09.11.2015 - 08:20 Uhr
Sprache: Deutsch
News-ID 432881
Anzahl Zeichen: 6228
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision AB: Interim Report January-September 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
